Volume 10, Number 9—September 2004
Research
SARS Antibody Test for Serosurveillance
Po-Ren Hsueh*1, Chuan-Liang Kao*1, Cun-Nan Lee*, Li-Kuan Chen†, Mei-Shian Ho‡, Charles Sia§¶, Xin De Fang§, Shugene Lynn¶, Tseng Yuan Chang§, Shi Kau Liu§, Alan M. Walfield§, and Chang Yi Wang§¶
Table 2
Sensitivity and specificity of peptide-based ELISAa
| Source of samples | Total no. | ELISA+ | ELISA– |
|---|---|---|---|
| Blood donors (Gulf Coast Regional Blood Bank, USA) | 1,390 | 0 | 1,390 |
| Blood-transmitted pathogen panel (various blood banks, USA) | 52 | 0 | 52 |
| Interference panel (BBI) | 41 | 0 | 41 |
| Confirmed SARS (TW CDC) | 69 | 69 | 0 |
| Influenza patients (NTU) | 10 | 0 | 10 |
| Influenza vaccinees (NTU) | 16 | 0 | 16 |
| Rubella patients (NTU) | 10 | 0 | 10 |
| EBV patients (NTU) | 9 | 0 | 9 |
| Mycoplasma (NTU) | 5 | 0 | 5 |
| CMV patients (NTU) | 8 | 0 | 8 |
aELISA, enzyme-linked immunosorbent assay; NTU, National Taiwan University; BBI, Boston Biomedica Inc (Boston, MA); TW CDC, Taiwan Center for Disease Control; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
